News in brief

Sabinsa gets patent on LactoSpore’s mood benefits

09-Dec-2019 - Last updated on 09-Dec-2019 at 17:48 GMT

Sabinsa photo

Related tags Depression Cognitive health Gut health Probiotics

Sabinsa has announced a new patent, this one for the effect of its Lactospore probiotic in the suppression depression symptoms in consumers suffering from gut health issues.

The patent, issued under the number US10166261, is for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans MTCC 5856 (LactoSpore) at a dose of 2 billion colony forming units per day.

The patent also mentions the ingredient’s ability to reduce serum myeloperoxidase, which is a biomarker of MDD.

The patent application was supported by a 2018 clinical study, published in the peer-reviewed journal Food & Nutrition Research titled “Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, doubleblind, placebo controlled, multi-centre, pilot clinical study.” The study showed LactoSpore was reported to reduce depression symptoms in adults with IBS.

“It is gratifying that the US patent office recognized the strain specific action of Sabinsa’s MTCC 5856 in allowing the claims,” said Shaheen Majeed, President Worldwide, Sabinsa. “We anticipate being granted patents on the discovery in additional countries in the near future.”